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Aims MMPs contribute to atherosclerotic plaque progression and instability, but the relative potency of their endogenous
tissue inhibitors of metalloproteinases (TIMPs) as protective factors has not been defined. We therefore investigated
the impact of TIMP-1 and TIMP-2 knockout on atherosclerotic plaque burden and composition in apolipoprotein
E-knockout (Apoe2/2) mice and studied the underlying effects on monocyte/macrophage behaviour.
Methods
and results
Analysis of brachiocephalic artery plaques revealed comparable atherosclerotic lesion areas between TIMP-12/2
Apoe2/2 or TIMP-22/2 Apoe2/2 double deficient mice and relevant age-matched, strain-matched Apoe2/2 controls
after 8 weeks of high-fat feeding. However, lesions from TIMP-22/2 Apoe2/2 mice had higher levels of markers asso-
ciated with plaque vulnerability, including increased macrophage: vascular smooth muscle cell ratios, larger necrotic
core areas, reduced collagen contents, increased macrophage proliferation, and apoptosis frequencies, compared
with TIMP-12/2Apoe2/2 and controls. In contrast, TIMP-12/2 Apoe2/2 animals only had a significant reduction in vas-
cular smooth muscle cell content compared with Apoe2/2 controls. In vitro and in vivo findings implicated heightened
monocyte/macrophage invasion in the detrimental effects observed on atherosclerotic plaque composition in TIMP-22/2
Apoe2/2 mice. Moreover, TIMP-2 specifically decreased MMP-14-dependent monocyte/macrophage infiltration into sites
of experimentally induced inflammation and established atherosclerotic lesions.
Conclusion Our data demonstrate that TIMP-2 plays a greater protective role than TIMP-1 during the pathogenesis of atheroscler-
osis, in part by suppressing MMP-14-dependent monocyte/macrophage accumulation into plaques.
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1. Introduction
Atherosclerotic plaque instability underlies the majority of myocardial
infarctions, most commonly through rupture of the fibrous cap.1 Pla-
que rupture results from excess hydrodynamic stress on a cap wea-
kened by breakdown of the extracellular matrix (ECM).2 Such
plaques are histologically characterized by large necrotic cores, a
high macrophage content in their fibrous caps, and a concomitant re-
duction in collagen and smooth muscle cell density.2 In atherosclerotic
plaques that are vulnerable to rupture, matrix degradation prevails, par-
ticularly at the macrophage-rich shoulder regions where secretion of
several MMPs is elevated while their endogenous tissue inhibitors
(TIMPs) are not, resulting in heightened proteolytic activity.3,4
Recruitment of fresh monocytes at sites distinguished as athero-
susceptible is one of the critical events in lesion formation and plaque
progression, although intra-plaque macrophage proliferation may also
play a prominent role in advanced lesions.5 Circulating monocytes dis-
play heterogeneity and can be phenotypically separated into at least
two distinct subsets in mice: ‘inflammatory’ monocytes are character-
ized by Ly6Chi CCR2hi CX3CR1lo cell-surface expression, whereas
‘patrolling’ monocytes exhibit a Ly6Clo CCR2lo CX3CR1hi profile.6 In
man, monocyte expression of CD14 and CD16 is used to delineate
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similar subsets.6 It has been postulated that the divergent monocyte
populations utilize proteases such as MMPs to permit their accumula-
tion at sites of inflammation including atherosclerotic plaques.7 Indeed,
MMP-12 and MMP-14 have both been demonstrated in vitro to regulate
monocyte/macrophage transmigration and invasion.8 – 11 MMP-14,
known also as membrane type-1 MMP (MT1-MMP), can direct peri-
cellular matrix degradation due to its membrane localization in an ac-
tive form.12 MMP-14 is also expressed by macrophages and foam-cell
macrophages within human atherosclerotic plaques13 and has been im-
plicated in acute myocardial infarction.14 Furthermore, loss- or
gain-of-function studies imply an important role for MMP-14 in plaque
stability.15,16 Consequently, MMP inhibitors could prove beneficial in
reversing the detrimental effects of MMP-14.
As their name suggests, TIMPs, which are expressed by numerous
vascular cell types within atherosclerotic plaques,17 tightly regulate en-
dogenous MMP activity. However, the prolonged presence of net MMP
activity in advanced plaques18,19 suggests that endogenous levels of
TIMPs are inadequate to achieve complete inhibition. Intriguingly,
TIMP-2 has been shown to inhibit MMP-14 activity, whereas TIMP-1
is less effective.20 Furthermore, overexpression studies have suggested
that TIMP-2 may retard monocyte/macrophage invasion and therefore
protect from plaque progression.21 Our current study aimed to com-
pare the roles of TIMP-1 and TIMP-2 in atherosclerotic plaque progres-
sion using knockout models, particularly focusing on their effects on
monocyte and macrophage invasion. We present novel data showing
that TIMP-2 but not TIMP-1 acts as an important modulator of the
MMP-14-directed monocyte/macrophage invasion that reduces accu-
mulation in atherosclerotic lesions in vivo and therefore plays a protect-
ive role during the pathogenesis of atherosclerosis. Our findings
indicate that MMP-14 is a pertinent therapeutic target for the preven-
tion of clinical atherosclerosis and other inflammatory diseases. Fur-
thermore, promoting TIMP-2 expression may represent an effective
strategy to inhibit MMP-14.
2. Methods
2.1 Animals
Male and female mice homozygous null for the Apoe gene on a 71% C57BL/
6J, 29% 129/SvJ background, were derived from a closed outbred colony
housed in the Animal Unit of the University of Bristol. Previously generated
TIMP-12/222 (background strain C57BL/6J; C57BL/6N) and TIMP-22/223
(background strain C57BL/6J) mice were kindly provided by Dr R Lijnen
(University of Leuven, Leuven, Belgium). Apoe2/2 mice were crossed
with TIMP knockouts to generate TIMP-12/2 Apoe2/2 and TIMP-22/2
Apoe2/2 double knockout mice as well as their relevant age-, strain-, and
sex-matched Apoe2/2 single knockout littermate controls. Genetic finger-
printing of tail tip DNA revealed the strain background of the breeding col-
onies was 69.7% C57BL/6J, 30.3% 129/SvJ for TIMP-1+/2 Apoe+/2 , and
(71.6% C57BL/6J, 28.4% 129/SvJ) for TIMP-2+/2 Apoe+/2 animals,
C57BL/6N strain was not detected. Genomic DNA was extracted from
tail tips for genotyping by PCR.
The housing and care of the animals and all the procedures used in these
studies were performed in accordance with the ethical guidelines and reg-
ulations of the University of Bristol and the UK Home Office. The investi-
gation conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication
No. 85–23, Eighth Edition, revised 2011). To evaluate any effect of TIMP
gene knockout on normal vessel development, subsets of animals were
fed standard chow diet from weaning for 6 weeks and then terminated.
To evaluate atherosclerosis, animals of 8 weeks of age were fed
high-fat diet containing 21% (wt : wt) pork lard and supplemented with
0.15% (wt : wt) cholesterol (Special Diet Services, Witham, UK) for
8 weeks. To ensure that the studies were adequately powered, group sizes
in excess of 20 animals were used.
Animals were anaesthetized by intraperitoneal injection of sodium
pentobarbitone (500 mg/kg of bodyweight) before exsanguination by per-
fusion via the abdominal aorta with PBS at a constant pressure of
100 mmHg, with outflow through the incised jugular veins. This was fol-
lowed by constant pressure perfusion with 10% formalin.
2.2 Plasma lipid profile
Plasma cholesterol levels were quantified as previously described,24 using the
BioVison Cholesterol Assay Kit (Cambridge BioSciences, Cambridge, UK).
2.3 Histology, plaque morphometrics, and
histological analyses
Sections (3 mm) were cut from the atherosclerosis-prone areas of brachio-
cephalic arteries and the aortic root as previously described.9 Sections
were subjected to immunohistochemical and morphometric analysis
(see Expanded Methods online).
2.4 In vitro studies on monocyte/macrophages
Freshly isolated mouse monocytes or 7-day M-CSF-differentiated macro-
phages were assessed by Q-PCR, flow cytometry, and immunocytochem-
istry for MMP-14 and monocyte/macrophage subset markers (see Expanded
Methods online). Gelatinolytic activity was assessed in cultured mouse
monocytes by in situ zymography, as described previously.25
2.5 In vitro invasion assay
Monocyte/macrophage invasion in vitro was assessed using MatrigelTM-
coated transwell inserts (Merck Millipore, Watford, UK) as described pre-
viously.25 Transwell inserts containing 8 mm pore membranes were coated
with 25 mL/well of MatrigelTM (BD Biosciences, Oxford, UK). Fifteen nano-
grams per millilitre of MMP-14 blocking antibody (BAb) (Millipore), purified
mouse recombinant-TIMP2 (10 mM) (Calbiochem), or mouse IgG (15 ng/
mL) was added to the Matrigel of the appropriate inserts. Monocyte/
macrophages were added to the upper portion of the transwell. RPMI/
FCS (600 mL) supplemented with 30 ng/mL of mouse recombinant mono-
cyte chemoattractant protein-1 (MCP-1) and 30 ng/mL of mouse recom-
binant Fractalkine (CX3CL1) (R&D System, Abingdon, UK) was placed in
the lower wells to induce transmigration/invasion. After 48 h, the number
of migrated/invaded cells were quantified and expressed as a percentage of
total cells.
2.6 In vivo monocyte/macrophage invasion
assay
TIMP-2WT and KOmicewere anaesthetised by inhalation with isofluorane
and 2–6 MatrigelTM (BD Biosciences, Oxford, UK) infused 1 cm3 polyur-
ethane sponges (Baxter Scientific, Newbury, Berkshire, UK) placed under
the dorsal skin for 11 days, and mice fed normal diet to allow the accumu-
lation of monocyte/macrophages as previously described.9 After 11 days,
the sponges were retrieved and fixed in 10% formalin, then subjected to
flow cytometry or immunohistochemistry for cell markers as deemed
necessary.
2.7 In vivo experiment for monocyte
recruitment into atherosclerotic lesions
Apoe2/2 mice (8 weeks of age, n ¼ 22) were fed a high-fat diet containing
21% (wt : wt) pork lard and supplemented with 0.15% (wt : wt) cholesterol
(Special Diet Services, Witham, UK) for 8 weeks. To assess monocyte/
macrophage recruitment to sites of inflammation, 8 of the 16 high-fat fed
mice, termed here after as ‘recipient’ mice, had three 1 cm3 polyurethane
sponges subcutaneously implanted as described above and returned to a
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high-fat diet for a further 8 days. Of the remaining mice, after 9 weeks of
high-fat feeding, monocytes were isolated by density gradient separation
and adhesion on plastic from n ¼ 6 and are here after referred to as ‘donor’
mice. Adherent monocytes were fluorescently labelled with Vybrant Car-
boxyfluorescein Diacetate, Succinimidyl Ester (CFDA SE) Cell Tracer Kit
(Invitrogen, Life Technologies, Paisley, UK) according to manufacturer in-
structions. Monocytes in suspension from each preparation were split
and then incubated with either mouse 15 mg/mL MMP-14 blocking anti-
body (Millipore, Watford, UK) or mouse IgG for 30 min at room tempera-
ture. Labelled monocytes (6.5 × 104 per mouse) pre-treated with and
without MMP-14 blocking antibody were injected into Apoe2/2-‘recipient’
mice via the tail vein (n ¼ 16, of which n ¼ 8 mice with subcutaneous
sponges). Animals were terminated 60 h after cell injection and samples
collected for subsequent analysis.
2.8 Statistical analysis
Values are expressed as mean+ S.E.M. Group values were compared using
the computer program InStat (GraphPad Software, San Diego, CA, USA).
For the comparison of group means, a check was first made for similar var-
iances: if this was passed then an unpaired two-sample two-tailed Student’s
t-test was carried out. If the variances were significantly different, then an
unpaired two-sample two-tailed t-test with Welch’s correction was used.
Statistical differences between monocyte/macrophages from the same
preparation were analysed by Student’s paired t-test. For the comparison
of multiple groups, an analysis of variance (ANOVA) test was used, and a
Student–Newman–Keuls multiple comparisons post hoc test employed
when statistical differences were detected. If a Bartlett’s test revealed
that the differences among the S.D. of groups were significant, a Kruskal–
Wallis non-parametric ANOVA was used and a Dunn post-test applied if
P, 0.05. Contingency data (presence of elastin breaks) were analysed by
Fisher’s exact test. In all cases, statistical significance was concluded where
the two-tailed probability was ,0.05.
3. Results
3.1 Effects of TIMP-1 or TIMP-2 deficiency
on morphometry of the brachiocephalic
artery in chow-fed animals
There were no significant differences in total vessel, medial, or luminal
areas between brachiocephalic arteries of TIMP-12/2 Apoe2/2 or
TIMP-22/2 Apoe2/2 double knockout mice compared with their re-
spective strain-matched Apoe2/2 controls, after 8 weeks of chow
diet (see Supplementary material online, Table S1). These findings
suggest that physiological development of the brachiocephalic artery
is unaffected by deficiency of individual TIMPs.
3.2 TIMP-2 but not TIMP-1 deficiency
aggravates markers of atherosclerotic
plaque instability
Immunohistochemistry of advanced brachiocephalic plaques from
8-week high-fat-fed mice revealed that 12.7+ 4.1 and 14.9+ 3.6% of
macrophages expressed TIMP-1 or TIMP-2, respectively (see Supple-
mentary material online, Figure S1). After 8-week high-fat feeding, no
significant differences in plasma lipids were observed between
TIMP-12/2 Apoe2/2 or TIMP-22/2 Apoe2/2 double knockout mice
and their respective strain-matched Apoe2/2 controls (see Supplemen-
tary material online, Table S2). No significant differences were observed
in any of the measured parameters within the brachiocephalic arteries
between TIMP-1+/+ Apoe2/2 and TIMP-2+/+ Apoe2/2 wild-type mice,
except for buried layers, which were less evident in TIMP-2+/+
Apoe2/2 animals (Table 1; see Supplementary material online, Figure
S2). Direct comparison between TIMP-12/2 Apoe2/2 and TIMP-22/2
Apoe2/2 mice revealed no differences in plaque size or vascular
smooth muscle cell content (Table 1; see Supplementary material on-
line, Figure S2 and Figure 1). However, plaques from both TIMP-12/2
Apoe2/2 and TIMP-22/2 Apoe2/2 mice demonstrated reduced vascular
smooth muscle cell content compared with wild-type control animals
(P, 0.01; Table 1; see Supplementary material online, Figure S2 and
Figure 1). Further analysis of brachiocephalic artery lesions from
TIMP-12/2 Apoe2/2 mice revealed no significant changes in all other
plaque composition parameters compared with TIMP-1+/+ Apoe2/2
and TIMP-2+/+ Apoe2/2 controls, respectively. Strikingly, TIMP-2 defi-
ciency led to a dramatic shift in plaque composition compared with
TIMP-12/2 Apoe2/2 (and both wild-type control mice; Table 1; see Sup-
plementary material online, Figure S2 and Figure 1). With regard to cel-
lular content, plaques from TIMP-22/2 Apoe2/2 mice exhibited a 33%
(P, 0.05) increase in macrophage number compared with TIMP-12/2
Apoe2/2 mice (Table 1; see Supplementary material online, Figure S2
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Table 1 Effects of TIMP-1 or TIMP-2 deficiency on Apoe2/2 mouse plaque area and characteristics after 8-week high-fat
feeding (n 5 24–29/group)
TIMP-11/1 Apoe2/2 TIMP-12/2 Apoe2/2 TIMP-21/1 Apoe2/2 TIMP-22/2 Apoe2/2
Lesion area ×103 mm2 (Brachiocephalic) 89+10 69+9 74+9 67+9
Macrophage (%) 16.8+3.6 28.4+10.5 21.6+3.1 37.8+4.0a,b,c
VSMC (%) 20.6+3.2 7.6+1.2a,b 16.8+1.7 9.0+1.2a,b
Collagen (%) 19.9+4.0 24.2+4.9 15.4+2.3 8.3+1.5a,b,c
Necrotic core (%) 19.3+2.6 24.7+2.7 18.9+3.7 36.4+3.4a,b,c
Apoptosis (%) 10.0+3.6 13.6+2.9 21.4+3.8 35.8+4.2a,b,c
Proliferation (%) 20.1+5.1 25.1+6.1 34.6+4.1 50.3+5.1a,b,c
Vulnerability index 1.1+0.2 0.6+0.2 0.8+0.1 0.2+0.1a,b,c
Buried layers 0.9+0.2 0.7+0.2 0.3+0.1a 0.8+0.1b
Elastin breaks 1/24 5/24 0/29 9/28a,b
aSignificant difference (P, 0.05) from TIMP-1+/+ Apoe2/2 mice.
bSignificant difference (P, 0.05) from TIMP-2+/+ Apoe2/2 mice.
cSignificant difference (P, 0.05) from TIMP-12/2 Apoe2/2 mice.
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and Figure 1). Conversely, picrosirius red staining of fibrillar collagens
and observation under polarized light revealed that plaque collagen
content was decreased (66%; P, 0.01) in TIMP-22/2 Apoe2/2 mice,
compared with TIMP-12/2 Apoe2/2 mice (Table 1; see Supplementary
material online, Figure S2 and Figure 1). A similar effect on collagen con-
tent was detected in comparison with TIMP-2+/+ Apoe2/2 controls,
presumably due to increased degradation as collagen production was
unaltered between aortic smooth muscle cells from either TIMP-2+/+
Figure 1 TIMP-2 deficiency retards brachiocephalic plaque progression and alters plaque composition. Representative images of histological sections
of brachiocephalic atherosclerotic plaques from 8-week high-fat-fed TIMP-1+/+ Apoe2/2 (i; n ¼ 24), TIMP-12/2 Apoe2/2 mice (ii; n ¼ 24), TIMP-2+/+
Apoe2/2 (iii; n ¼ 28), and TIMP-22/2 Apoe2/2 mice (iv; n ¼ 29). Sections are histochemically or immuno-stained for CD68 (macrophages; A), a-smooth
muscle actin (vascular smooth muscle cells, B), picrosirius red (collagen; C ), haematoxylin and eosin (D), cleaved caspase-3 (green) and CD68 (red)
(apoptosis; E), PCNA (green) and CD68 (red) (proliferation; F ), or elastin van Gieson (G). Scale bar in Ai represents 100 mm and is applicable to
A–D and G. Scale bar in Ei represents 50 mm and is applicable to all panels in E and F. Insets in C (i – iv) are matching brightfield images of picrosirius
red stained sections of the relevant panels. Areas depicted by dotted lines in D (i– iv) represent the relative necrotic core area assessed. Arrows in E
and F highlight apoptotic and proliferating macrophages, respectively, while nuclei are counterstained with DAPI (blue).
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or TIMP-22/2 mice (see Supplementary material online, Figure S3), even
after phenotypic switching with PDGF-BB and IL-1b (see Supplemen-
tary material online, Figure S3).We next evaluated the size of the plaque
necrotic core by measuring the area of haematoxylin-negative, acellular
areas in the intima26 and observed that TIMP-2 deficiency was asso-
ciated with a significant increase in necrotic core size (47%; P, 0.01;
Table 1; see Supplementary material online, Figure S2 and Figure 1), com-
pared with TIMP-12/2 Apoe2/2 mice. Consistently, we detected a sig-
nificantly increased frequency of macrophages undergoing apoptosis in
plaques from TIMP-22/2 Apoe2/2 mice relative to TIMP-12/2 Apoe2/2
animals (P, 0.01; Table 1; see Supplementary material online, Figure S2
and Figure 1). However, because macrophage accumulation was in-
creased in spite of the increased frequency of apoptosis, we also as-
sessed proliferation indices. Indeed, heightened lesional macrophage
proliferation has been proposed to drive murine atherosclerotic plaque
progression.5 The number of macrophages assessed to be undergoing
proliferation was increased within lesions of TIMP-22/2 Apoe2/2-
related TIMP-12/2 Apoe2/2 mice (100%; P, 0.01; Table 1; see Supple-
mentary material online, Figure S2 and Figure 1). Collectively, TIMP-2
deficiency resulted in alterations in plaque composition that have
been previously taken as markers of increased plaque instability. Con-
sistent with this, the lesion compositional changes translated to a heigh-
tened plaque vulnerability index27 in mice lacking TIMP-2, compared
alongside TIMP-1-deficient mice and wild-type control animals (Table 1;
see Supplementary material online, Figure S2). We additionally counted
buried fibrous layers (VSMC-rich layers invested with elastin that over-
lay foam-cell macrophages), which have been postulated as another
surrogate marker of plaque vulnerability in mice24 and humans.28
Our analysis revealed no difference between TIMP-12/2 Apoe2/2
and TIMP-22/2 Apoe2/2 mice, although a significant 2.3-fold increase
in the number of plaques containing buried fibrous layers from
TIMP-22/2 Apoe2/2 compared with TIMP-22/2 Apoe2/2 mice was
observed (Table 1; see Supplementary material online, Figure S2 and
Figure 1). Similarly, no alterations in evidence of elastin fragmentation
was seen between TIMP-12/2 Apoe2/2 and TIMP-22/2 Apoe2/2 mice,
whereas more prevalent elastin fragmentation was detected in both
the atherosclerotic brachiocephalic arteries (Table 1; see Supplementary
material online, Figure S2 and Figure 2) and at the aortic root (see Sup-
plementary material online, Figure S4) of TIMP-22/2 Apoe2/2 mice com-
pared with TIMP-22/2 Apoe2/2 mice animals.
3.3 TIMP-2 but not TIMP-1 deficiency
retards monocyte/macrophage invasion
Due to the striking differences in macrophage accumulation within pla-
ques of mice deficient in TIMP-2, as opposed to TIMP-1 knockout ani-
mals, compared with their relevant wild-type controls (Table 1 and
Figure 2 TIMP-2 deficiency induces elastin fragmentation. (A–C) Representative images of serial sections from an atherosclerotic brachiocephalic ar-
tery with a marked elastin fragmentation (black arrowhead in A) which have been immunohistochemical stained for (A) elastin van Gieson, (B) smooth
muscle cells, or (C) macrophages from a TIMP-22/2 Apoe2/2 mouse. (D) Quantification of the number of TIMP-2+/+ Apoe2/2 and TIMP-22/2 Apoe2/2
mice without (black bars) or with (red bars) elastin breaks (*P, 0.05; n ¼ 27/28 per group; data expressed as mean+ SEM). Scale bar in A represents
100 mm and is applicable to all panels.
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Figure 1), we assessed the roles of TIMP-1 and TIMP-2 on monocyte in-
vasion in vitro and in vivo. Accordingly, monocyte invasion through a
Matrigel-coated transwell chamber in response to MCP-1 and
fractalkine-induced chemo-attraction21 was significantly increased by
monocytes from TIMP-22/2 mice showed more invasion in vitro
when compared with TIMP-2+/+ wild-type cells (2-fold increase; P ≤
0.05; Figure 3A). In contrast, invasion of TIMP-12/2 monocytes was
comparable to TIMP-1+/+ wild-type controls (Figure 3A). Furthermore
and consistent with our in vitro data, the number of monocyte/macro-
phages recruited into Matrigel-infused sponges was unaffected be-
tween TIMP-12/2 and TIMP-1+/+ wild-type control mice (Figure 3B),
whereas significantly increased monocyte/macrophage accumulation
was observed in TIMP-22/2 mice compared with TIMP-2+/+ wild-type
controls (4.3-fold; P, 0.001, Figure 3B). These data support a key role
for TIMP-2 in arresting monocyte invasion and may explain the ob-
served increase in macrophage numbers within brachiocephalic
plaques of TIMP-22/2 mice.
3.4 MMP-14 is expressed by CX3CR1hi/
CCR2lo/Ly6Clo monocytes but is rapidly
up-regulated in allmonocytes after adhesion
We have previously demonstrated that systemic adenoviral-mediated
overexpression of TIMP-2, but not TIMP-1, can modulate intra-plaque
Figure 3 TIMP-2 deficiency retards monocyte/macrophage invasion. (A) Representative CD11b IHC-labelled Matrigel-coated invasion inserts and
quantification of TIMP-1+/+, TIMP-12/2, TIMP-2+/+ and TIMP-22/2 monocyte invasion in vitro (n ¼ 4; *P, 0.05 denotes significant difference from
all other groups). Scale bar represents 50 mm and is applicable to all panels. (B) Representative CD11b IHC-labelled images and quantification of macro-
phage number within subcutaneous sponges from TIMP-1+/+, TIMP-12/2, TIMP-2+/+ and TIMP-22/2 mice, and TIMP-22/2 mice with sponges containing
an MMP-14-blocking antibody (BAb; 15 ng/mL) (n ¼ 6 per group; ***P, 0.001 denotes significant difference from all groups; ###P, 0.001 denotes
significant difference from TIMP-22/2 mice). Scale bar represents 50 mm and is applicable to all panels.
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gelatinolytic activity.21 In addition, exogenous TIMP-2 retarded in vitro
monocyte/macrophage invasion, whereas TIMP-1 was ineffective.21 Ta-
ken together with our current findings, these results imply that TIMP-1
and TIMP-2 exert disparate inhibitory effects. It is known that TIMP-1
poorly inhibits type I MT-MMPs, such as MMP-14,215,216, and224,
but are effectively inhibited by TIMP-2.20 Accordingly, we assessed the
expression of the four type I MT-MMPs in monocytes and mature
macrophages. QPCR analysis revealed that MMP-14 is significantly
more abundant in monocytes and macrophages than other type I
MT-MMPs (see Supplementary material online, Figure S5A). Similarly,
a greater number of macrophages within the shoulder regions of
mouse brachiocephalic plaques expressed MMP-14 than MMP-15,
216, or 224 (see Supplementary material online, Figure S5B), implying
a prominent role for MMP-14 in monocyte/macrophage accumulation.
Indeed, MMP-14 has been directly implicated in the migration/invasion
of monocytes through the endothelium.10 We therefore assessed
whether TIMP-2-dependent MMP-14 activity regulated the migration/
invasion of monocyte/macrophages in vitro and in vivo, and therefore un-
derlies the observed detrimental effects on atherosclerosis observed in
TIMP-22/2 Apoe2/2 mice. In the first instance, we measured MMP-14
expression in circulating and adherent monocytes. Immunocytochem-
ical and flow cytometry analysis showed that MMP-14 is expressed in
only 18+ 4% of circulating non-adherent monocytes (Figure 4A and
see Supplementary material online, Figure S6A). Dual labelling with re-
cognized markers of well-characterized murine monocyte subsets
(Ly6C, CCR2, and CX3CR1) revealed that MMP-14 expression is
not associated with Ly6C- or CCR2-positive monocytes (1+ 0.8%
MMP-14+Ly6C+ and 6+ 2% MMP-14+CCR2+ double positive
cells, respectively; P, 0.05; Figure 4A). Conversely, the majority of
MMP-14 positive monocytes co-expressed CX3CR1 (99.7+ 0.2%
MMP-14+CX3CR1+; P, 0.001; Figure 4A and see Supplementary ma-
terial online, Figure S6B). These findings imply that MMP-14 serves as an
additional marker of the LyC6lo CCR2lo CX3CR1hi monocyte subset
that performs a patrolling role in early responses to cell injury and in-
fection29 and also in tissue repair after ischaemic injury.30 Interestingly,
upon adhesion to plastic MMP-14, mRNA was significantly up-
regulated (P ≤ 0.05; Figure 4B) and consequently the percentage of
MMP-14 positive cells was increased 4.4-fold (P ≤ 0.001) compared
with non-adherent cells (Figure 4C). Moreover, no difference in mono-
cyte MMP-14 immuno-positivity was identified between non-
permeabilized and permeabilized cells (Figure 4C), implying that
MMP-14 is localized to the cell membrane ready to facilitate cell inva-
sion.11 Finally, the percentage of CCR2 positive monocytes after cell
adhesion was significantly increased by 1.9-fold (P, 0.01; Figure 4D)
to a comparable level of CX3CR1, indicating that upon adhesion,
monocytes respond to MCP-1 and fractalkine chemo-attraction, irre-
spective of Ly6C expression.
3.5 MMP-14 promotes and TIMP-2 retards
monocyte invasion and recruitment in vitro
and in vivo
To test our hypothesis that increased MMP-14 expression endows
monocyte/macrophages with an enhanced migratory capacity, we mea-
sured MMP-14 activity and performed in vitro migration assays. In situ
zymography revealed that adherent monocytes exhibited abundant
MMP-14-dependent gelatinolytic activity, which could be significantly
reduced by co-incubation with an MMP-14-neutralizing antibody,
when compared alongside IgG-treated control cells (three-fold
decrease; P ≤ 0.01; Figure 5A). MMP-2 and MMP-9 are also potent ge-
latinases; however co-incubation with inhibitors to either of these
MMPs failed to diminish the gelatinolytic activity observed in control
monocytes (Figure 5A). Monocyte invasion through a Matrigel-coated
transwell chamber in response to MCP-1 and fractalkine-induced
chemo-attraction21 was significantly retarded in the presence of an
MMP-14-neutralizing antibody (91+ 4% reduction; P ≤ 0.01;
Figure 5B), mouse recombinant TIMP-2 (81+ 10% reduction; P ≤
0.01; Figure 5B), or when given in combination (77+ 8% reduction;
P ≤ 0.01; Figure 5B). Conversely treatment with either an MMP-2 or
MMP-9 inhibitor failed to retard monocyte invasion compared with ex-
ogenous TIMP-2 (Figure 5C). These data suggest that inhibition of
monocyte MMP-14 activity by endogenous TIMP-2 retards their inva-
sion and may explain the observed increase in macrophage numbers
within brachiocephalic plaques of TIMP-22/2 mice.
To extend our findings into an in vivo model, we examined the
effect of MMP-14 inhibition on monocyte/macrophage recruitment
in a subcutaneous granuloma invasion assay.9 In line with our in vitro
observations, the number of monocyte/macrophages present in
Matrigel-infused subcutaneous sponges was significantly reduced by
2.4-fold (P ≤ 0.001) and 2.1-fold (P ≤ 0.002), respectively, as assessed
by the number of CD11b- or CD68-positive nucleated cells, in the
presence of an MMP-14-neutralizing antibody compared with IgG con-
trol sponges (Figure 6A). Furthermore, MMP-14 inhibition significantly
reduced the average distance of monocyte/macrophage invasion into
sponges (1.6-fold decrease; P ≤ 0.001; Figure 6A) compared with con-
trols. We also assessed the potential contributory role of altered
intra-sponge monocyte/macrophage proliferation and/or apoptosis to
the observed reduction in cell accumulation. However, using validated
markers (cleaved caspase-3 and PCNA), apoptosis or proliferation
markers were negligible in monocyte/macrophages of sponges in the
presence of an MMP-14-neutralizing antibody or IgG controls (data
not shown). Additionally, circulating monocyte numbers were not al-
tered between mice receiving either MMP-14-neutralizing antibody
or IgG control-infused sponges (see Supplementary material online,
Figure S7A). Taken together, these findings strongly imply that
MMP-14 directly permits monocyte/macrophage invasion in vivo.
To corroborate and relate our findings to atherosclerosis, we in-
vestigated whether nullifying MMP-14 impedes monocyte recruit-
ment into plaques. Accordingly, we performed an in vivo adoptive
transfer experiment (using a previously described method31). We
intravenously injected hypercholesterolaemic Apoe2/2 mice har-
bouring pre-existing atherosclerotic plaques with fluorescently la-
belled monocytes retrieved from the circulation of donor mice.
Monocytes were pre-incubated or not with an MMP-14-neutralizing
antibody. Recipient mice showed no apparent adverse effects, and
we isolated brachiocephalic arteries 60 h after the injections. We ana-
lysed histological sections of the proximal brachiocephalic artery
with light and fluorescent microscopy for labelled macrophages that
were adherent to or within the atherosclerotic plaques. Consistent
with the data from the in vitro invasion assays and in vivo sponge ex-
periments, the number of fluorescent monocytes recruited into
brachiocephalic artery plaques was significantly reduced 8.7-fold
(P ≤ 0.01; Figure 6B) when MMP-14 activity was neutralized. As a fur-
ther internal control for the adoptive transfer experiment, a propor-
tion of labelled monocytes were used for an in vitro invasion assay.
Monocytes pre-treated with MMP-14 blocking antibody demon-
strated a 1.9-fold reduced ability to invade a synthetic matrix com-
pared with IgG pre-treated, control monocytes (P , 0.05; see
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Supplementary material online, Figure S7B). Collectively, these data
strongly suggest a predominant role for MMP-14 in mediating mono-
cyte recruitment and macrophage accumulation within established
atherosclerotic plaques, highlighting both MMP-14 and its inhibitor,
TIMP-2, as potential therapeutic avenues for the treatment of
unstable atherosclerotic lesions.
3.6 TIMP-2 diminishes macrophage
apoptosis and retards MMP-14-dependent
N-cadherin cleavage
We observed that atherosclerotic plaques from TIMP-22/2 Apoe2/2
exhibited heightened frequencies of macrophage apoptosis compared
Figure 4 MMP-14 is expressed by Ly6Clo monocytes but is rapidly up-regulated in all monocytes after adhesion. (A) Co-labelling and quantification of
MMP-14 with (I) Ly6C, (II) CCR2, and (III) CX3CR1 in CD11b positively selected monocytes. Grey bars in graphs represent MMP-14-negative mono-
cytes while green bars signify MMP-14 positive cells (*denotes P, 0.05 and ***denotes P, 0.001; n ¼ 6). Scale bar represents 50 mm and is applicable
to all panels. (B and C) QPCR for MMP-14 mRNA expression (B) and representative immunohistochemical labelling and quantification of MMP-14 pro-
tein expression, in non-adherent and adherent monocytes (n ¼ 4; ***P, 0.001 and represents significant difference from non-adherent monocytes).
Scale bar represents 50 mm and is applicable to both panels. (D) Quantification of non-adherent and adherent monocyte Ly6C, CCR2, and CX3CR1
expression (n ¼ 4; *P, 0.05).
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with Apoe2/2 controls (Table 1 and Figure 1). In an attempt to elucidate
the underlying mechanisms by which TIMP-2 impedes macrophage
apoptosis, macrophages from TIMP-22/2 and TIMP-2+/+ control mice
were subjected to LPS-induced apoptosis. In accordance with our his-
tolological findings, the absence of TIMP-2 increased macrophage
apoptosis by 6-fold (8.2+ 4.4 vs. 49.4+ 3.3%; P ≤ 0.001; n ¼ 5).
Figure 5 TIMP-2 retards MMP-14-dependent monocyte invasion in vitro. (A) Quantification of gelatinolytic activity, as assessed by in situ zymography of
monocytes incubated with substrate plus goat IgG (control), 15 ng/mL MMP-14 blocking antibody (BAb), DMSO (control), MMP-2 inhibitor. (MMP-2i;
1 nM), or MMP-9 inhibitor. (MMP-9i; 5 nM) Green fluorescence represents gelatinolytic activity (**P, 0.01 and denotes significant difference from IgG
control; n ¼ 6 per group; data expressed as mean+ SEM). (B) Representative Matrigel-coated invasion inserts and quantification of monocyte invasion
with and without an MMP-14 blocking antibody, (BAb; 15 ng/mL), recombinant TIMP-2 (5 nM), or both, and incubated for 48 h (n ¼ 4; **P, 0.01
denotes significant difference from IgG control). (C) Representative Matrigel-coated invasion inserts and quantification of monocyte invasion with
and without MMP-2 inhibitor (MMP-2i; 1 nM), or MMP-9 inhibitor (MMP-9i; 5 nM), plus recombinant TIMP-2 (5 nM), and incubated for 48 h (n ¼ 4;
*P, 0.05 denotes significant difference from IgG control, MMP-2i and MMP-9i). Scale bar represents 50 mm and is applicable to all panels.
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Consequently, western blotting for the pro-survival protein N-cadherin
was conducted to gain mechanistic insight into the anti-apoptotic
effect of TIMP-2, as we have previously demonstrated that MMP-
mediated cleavage of N-cadherin can induce macrophages apop-
tosis.9,32 We demonstrate that GM-CSF stimulation of macrophages,
which we have previously shown induces MMP-14 activity and apop-
totic frequencies,16 induces the generation of cleaved N-cadherin
expression in macrophages, but this is reversed in the presence of
exogenous TIMP-2 (P, 0.01; see Supplementary material online,
Figure S8). Moreover, addition of an MMP-14-blocking antibody alone
or in combination with exogenous TIMP-2 negated the formation of
the cleaved fragment of N-cadherin observed in the presence of
GM-CSF (P, 0.05 and P, 0.01, respectively; see Supplementary
material online, Figure S8). The additive effect may suggest that other
proteases capable of N-cadherin cleavage, such as MMP-12,9 are
amenable to TIMP-2 inhibition. Indeed, it has recently been demon-
strated that TIMP-2 can retard MMP-12 activity.33
4. Discussion
It is considered that protease inhibitors most probably play an import-
ant protective role, during atherosclerosis, although there is no con-
sensus about their relative importance. Our current findings clearly
demonstrate disparate roles for TIMP-1 and TIMP-2 in plaque
Figure 6 TIMP-2 retards MMP-14-dependent monocyte invasion in vivo. (A) Representative CD11b IHC-labelled images (I and II) and quantification of
macrophage density (III) and invasion depth (IV), in an in vivo subcutaneous sponge invasion assay, in the presence of an MMP-14-blocking antibody (BAb;
15 ng/mL) compared with IgG controls (dotted line represents edge of sponge; n ¼ 6 per group; **P, 0.01 denotes significant difference from IgG
control-infused sponges). Scale bar represents 50 mm and is applicable to both panels. (B) Assessment of fluorescently labelled monocytes pre-treated
with or without an MMP-14-blocking antibody (BAb; 15 ng/mL), in established atherosclerotic lesions (n ¼ 6 per group; *P, 0.05 denotes significant
difference from IgG control; white arrows indicate labelled monocytes). Scale bar represents 50 mm.
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evolution. We show that loss of TIMP-1 expression has no major effect
on plaque size or composition in the brachiocephalic artery of Apoe2/2
mice, except for reducing smoothmuscle cell content. In contrast, mice
with no functional TIMP-2 gene have more complex plaques and ex-
hibit several compositional changes associated with increased plaque
vulnerability compared with TIMP-1-deficient mice, as well as
Apoe2/2 wild-type controls. Similarly, while TIMP-1 does not substan-
tially regulate monocyte/macrophage invasion, TIMP-2 exerts a major
inhibitory role. These findings strongly imply a prominent role for en-
dogenous levels of TIMP-2 in the reduction of atherosclerotic plaque
development and progression, particularly through the retardation of
monocyte/macrophage accumulation, presumably through MMP inhib-
ition. Indeed, we show for the first time that monocyte/macrophage ac-
cumulation within established mouse atherosclerotic plaques is
MMP-14 dependent. Moreover, MMP-14-mediated monocyte invasion
in vitro and in vivo is restricted by endogenous levels of TIMP-2. The con-
tinual accumulation of monocyte/macrophages with their associated
heightened proteolytic repertoire is considered fundamental to the de-
velopment, progression, and destabilization of atherosclerotic
plaques.34,35
The minor effects of TIMP-1 knockout we observed on plaque size
and composition are in broad agreement with previous findings.21,36,37
In one study, modest increases in macrophage and lipid content were
reported in lesions at the aortic root of TIMP-12/2 Apoe2/2 mice rela-
tive to Apoe2/2 controls, despite a paradoxical reduction in plaque
size.38 The discrepancy with our findings could be owing to minor dif-
ferences in strain background and diet in the two studies. Overexpres-
sion of TIMP-1 also reduced atherosclerotic plaque size at the aortic
root of Apoe2/2 mice in one study,39 but this effect was not replicated
in another.37 In neither of these overexpression studies were effects on
plaque composition quantified. However, the study from Lemaitre and
colleagues did suggest that plaque smooth muscle cell numbers were
diminished in TIMP-12/2 Apoe2/2 mice,36 which is in agreement with
our current findings. It is plausible that TIMP-1 promotes cell survival
through the inhibition of MMP-7. TIMP-1 has been shown to potently
retard MMP-7 activity,40 while MMP-7 can generate active soluble Fas-
Ligand (FasL),40 an effective inducer of smooth muscle cell apoptosis41
Furthermore, we have shown previously that MMP-7 can cleave
N-cadherin and promote smooth muscle cell apoptosis.42 Accordingly,
we observed reduced frequencies of smooth muscle cell apoptosis in
plaques from MMP-72/2 Apoe2/2 mice,42 associated with increased
smooth muscle cell number, but no discernible effects on plaque
area or other compositional elements,43 consistent with our observa-
tions in TIMP-12/2 Apoe2/2 mice. Taken together, the studies imply a
small role at best for TIMP-1 in plaque evolution in mice.
The dramatic shift in brachiocephalic plaque composition towards
vulnerability caused by deletion of TIMP-2 accords with a previous
study, which intimated that overexpression of exogenous TIMP-2 fa-
vourably affects plaque phenotype, possibly through modulation of
macrophage behaviour.21 However, the potential beneficial anti-
proteolytic effects afforded from elevated exogenous TIMP-2 levels
on murine atherosclerosis were not fully elucidated, although the in-
volvement of gelatinolytic MMPs were implied by in situ zymography.
Nonetheless, overall TIMP-2 seems to be a much more important de-
terminant of plaque stability than TIMP-1. It must be noted that the
number of buried layers within atherosclerotic lesions were not differ-
ent between TIMP-1- and TIMP-2-deficient mice, although a difference
was observed between the TIMP-1 and TIMP-2 wild-type controls. We
believe this is as a result of slight genetic drift between the founder
mice, as we have previously observed differences in the number of
intra-plaque buried fibrous layers between MMP wild-type mice gener-
ated for knockout mouse studies.43
Despite similar structural properties, functional differences between
TIMP-1 and TIMP-2 have been reported.44 For example, TIMP-1 dis-
plays poor inhibitory capacity towards membrane-type (MT) MMPs,
whereas these are completely inhibited by TIMP-2.20 The striking dif-
ferences observed between TIMP-1 and TIMP-2 deficiency are there-
fore most easily explained by disparate inhibitory effects on specific
MMPs. Several reviews have highlighted the different roles of specific
MMPs that emerge from knockout studies in the same Apoe2/2 back-
ground.17,45 For example, we previously demonstrated that MMP-3,
MMP-7, MMP-9, and MMP-12 exert highly divergent effects on athero-
sclerotic plaque development, particularly cellular composition, in mice
studied under very similar conditions.43 MMP-14, also known as
MT1-MMP, has been linked to atherosclerosis progression and plaque
vulnerability in mice15,16 owing to its ability to deplete collagen.
MMP-14 has also been observed in human plaques where its abun-
dance associates with markers of greater vulnerability.13,46 Additionally,
MMP-14 has been shown to cluster at the lamellipodia of migrating
monocytes, and inhibition of MMP-14 activity (either by neutralizing
antibody or gene silencing) retards in vitro monocyte transmigration
through activated endothelium.10,11 Previous studies have also demon-
strated that broad spectrum MMP inhibitors or TIMP-2 suppress
mononuclear cell transmigration in vitro and in vivo, whereas TIMP-1 is
ineffective.11,21,47 Accordingly, we hypothesized that the loss of TIMP-2
in mice might result in heightened monocyte/macrophage MMP-14
activity, facilitating macrophage accumulation within atherosclerotic
lesions and thereby provoking the detrimental shift in plaque
composition.
Consistent with this hypothesis, our present results demonstrate for
the first time that only LyC6lo CCR2lo CX3CR1hi monocytes constitu-
tively express cell-surface MMP-14. Indeed, our findings show that
MMP-14 may serve as an additional marker of the LyC6lo CCR2lo
CX3CR1hi monocyte subset that performs a patrolling role in early re-
sponses to vascular29 and myocardial injury.30 However, upon adher-
ence, the majority of monocytes, including the LyC6hi CCR2hi
CX3CR1lo subset, acquire activated and cell-membrane-localized
MMP-14, which is therefore available to facilitate cell invasion in
response to MCP-1 and/or fractalkine chemo-attraction.11 Hence,
although divergent monocyte subsets may display disparate levels
of other MMPs,7 adherence modulates MMP-14 expression irrespect-
ive of monocyte subset. Our in vitro and in vivo data yield strong evidence
that MMP-14 facilitates the invasion of adherent monocyte/macrophages
in a TIMP-2-dependent manner. Indeed we demonstrate for the first
time that in vivo macrophage invasion is augmented in the absence of
TIMP-2, but not TIMP-1. This novel finding supports our previous stud-
ies, in which exogenous TIMP-2 expression retarded in vitro monocyte/
macrophage invasion.21
The present study also demonstrates a specific effect of MMP-14 ac-
tivity on monocyte/macrophage accumulation within murine athero-
sclerotic lesions. We therefore postulate that heightened MMP-14
activity afforded by loss of TIMP-2 underpins the increasedmacrophage
content observed within brachiocephalic plaques of TIMP-22/2
Apoe2/2 mice when matched to TIMP-2+/+ Apoe2/2 controls or
TIMP-12/2 Apoe2/2 mice. Supporting findings were observed in a
mouse model of myocardial infarction, where TIMP-2-deficient mice
exhibit increased monocyte/macrophage infiltration alongside heigh-
tened MMP-14 expression and activity, promoting adverse disease
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progression compared with wild-type controls.48 Also, the observation
that increased elastin fragmentation alongside macrophage infiltration
was more evident in atherosclerotic plaques of TIMP-2-deficient
mice, implies a protective role for TIMP-2 in the pathogenesis of aortic
aneurysms. Finally, increased monocyte/macrophage accumulation
within atherosclerotic plaques is related with heightened macrophage
proliferation5 and augmented frequencies of apoptosis.49 Hence, we
can postulate that loss of TIMP-2 and associated increased MMP-14 ac-
tivity promotes monocyte/macrophage accumulation within develop-
ing plaques, and consequent macrophage apoptosis (through
TIMP-2-dependent MMP cleavage of N-cadherin for example) induces
further monocyte recruitment via the release of numerous chemotac-
tic factors.49Ensuing plaque progression associated with necrotic core
expansion has been shown to favour heightened local macrophage pro-
liferation.5 This tenet is in accordance with our findings where TIMP-2
deficiency results in advanced plaques exhibiting increasedmacrophage
number alongside amplified rates of macrophage proliferation and
augmented frequencies of macrophage apoptosis.
We cannot discount the inhibitory effects of TIMP-2 on other MMPs,
particularly type I MT-MMPs, which might contribute to our observed
effects. Indeed recent studies50,51 have demonstrated the expression
of other type I MT-MMP family members (MMP-15, 216, and 224)
in human atherosclerotic plaques, although their direct role in mono-
cyte recruitment and plaque progression await the appropriate experi-
mentation. However, our findings that MMP-14 is substantially greater
expressed by monocytes and macrophages imply that the other type I
MT-MMPs play a minor role. Additionally the gelatinases MMP-2 and
29 also appear to play negligible roles in monocyte/macrophage gela-
tinolytic activity and associated invasion. Furthermore, we previously
demonstrated that MMP-14 is the most abundant MMP in activated
macrophages.52 Indeed, the fact that we were able to inhibit monocyte
recruitment in vivo with a specific antibody against MMP-14 demon-
strates that it plays an indispensable role. It is also possible that the
beneficial effects TIMP-2 exert on atherosclerosis may be through
the suppression of numerous proteolytic substrates and the modula-
tion of other resident cell types within atherosclerotic lesions. While
atherosclerotic plaque smooth muscle cells and endothelial cells have
been shown to express TIMP-2, endothelial cell TIMP-2 expression is
decreased compared with healthy vessels.3 MMP-14 is also expressed
by plaque smooth muscle cells and endothelial cells, but to a lesser de-
gree than macrophages.53,13 Moreover, with regard to the contribution
of endothelial cell-derived TIMP-2 and/or MMP-14 to monocyte migra-
tion, Sithu and colleagues54 demonstrated that either endothelial cell
or monocyte-derived TIMP-2 could reduce monocyte transmigration,
while in support of our own findings TIMP-1 could not. Similarly,
MMP-14 in endothelial cells or monocytes promoted transmigration
(via ICAM-1 cleavage), which could be blocked by TIMP-2, but not
TIMP-1. Accordingly, effects on endothelial cell-derived TIMP-2 and/
or MMP-14 may also in part contribute to the observed effects in vivo.
In conclusion, our current findings in double knockout mice highlight
varying roles for different members of the TIMP family in atheroscler-
otic plaque development and progression. The fact that TIMP-2 plays a
protective role while that of TIMP-1 is minimal, supports the tenet that
differing MMPs impart divergent effects on atherosclerosis.43 More-
over, we provide strong evidence for a detrimental role of mono-
cyte/macrophage MMP-14 expression/activity in atherosclerotic
plaque development and progression, and illustrate it as a therapeutic
target. In association, promoting TIMP-2 expression may serve as an ef-
fective avenue to retard monocyte recruitment to sites of inflammation
such as atherosclerotic plaques, while additionally perturbing intra-
plaque MMP activity and increasing lesion stability.
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